<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04123340</url>
  </required_header>
  <id_info>
    <org_study_id>NL69217.058.19</org_study_id>
    <nct_id>NCT04123340</nct_id>
  </id_info>
  <brief_title>Intraprocedural Assessment of Ablation Margins Using Computed Tomography Co-registration in Primary Liver Tumor Treatment With Percutaneous Ablation</brief_title>
  <acronym>IAMCOMPLETE</acronym>
  <official_title>Intraprocedural Assessment of Ablation Margins Using Computed Tomography Co-registration in Primary Liver Tumor Treatment With Percutaneous Ablation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mirada Medical</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Leiden University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A pre- and postablation scan will be made intraprocedurally to investigate the feasibility of
      intraprocedural ablation verification assessment using coregistration software
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 27, 2019</start_date>
  <completion_date type="Anticipated">October 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>prospective, single blind, single-arm, phase II stud</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>post-procedural an assessment will be done of the ablation completeness using registration software. The actual ablation verification will be done qualitatively by the treating physician.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of the use of co-registration software (&gt;90%)</measure>
    <time_frame>1 year</time_frame>
    <description>The proportion of patients in whom reliable co-registration with MIRADA RTx of pre- and post-ablation CT images is feasible</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inter and intra-observer variability</measure>
    <time_frame>1 year</time_frame>
    <description>Inter- and intraobserver variability of CT-CT co-registration of determining the minimum ablation margin after thermal ablation for liver tumors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time that is required for CT-CT co-registration</measure>
    <time_frame>1 year</time_frame>
    <description>The time that is required for CT-CT co-registration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitatively assessed ablation margin</measure>
    <time_frame>1 year</time_frame>
    <description>Percentage of local recurrence per group as categorized according to ablation margin: &lt;0mm, 0-5mm, &gt;5mm</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>HCC</condition>
  <arm_group>
    <arm_group_label>Additional intraprocedural CT-scan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Additional intraprocedural CT-scan</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Additional intraprocedural pre-ablation CT-scan</intervention_name>
    <description>In 20 patients, besides de regular post-RFA scan, a pre-RFA contrast enhanced dual phase CT-scan will be acquired to investigate the feasibility of quantitative ablation assessment.</description>
    <arm_group_label>Additional intraprocedural CT-scan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 yrs or above

          -  HCC very early (0) or early stage (A) according to the BCLC staging system

          -  Either de novo or recurrent HCC (prior locoregional therapy is allowed in the study)

          -  Candidate for percutaneous thermal ablation as discussed in a multidisciplinary tumor
             board. Ablation as 'bridge-to-transplant' is allowed in the study

        Exclusion Criteria:

          -  Estimated GFR &lt;30 ml/min

          -  Morbid obesitas or any pulmonary condition that is a contraindication to prolonged
             apnea and high jet-ventilation

          -  Child Pugh C

          -  Portal vein tumor invasion

          -  Extrahepatic metastasis

          -  Uncorrectable coagulopathy

          -  Any psychological, familial, sociological or geographical condition potentially
             hampering compliance with the study protocol and follow-up schedule

          -  Inability or unwillingness to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mark C. Burgmans, MD, PhD</last_name>
    <phone>+31-71 5262410</phone>
    <email>m.c.burgmans@lumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pim Hendriks, MSc.</last_name>
    <phone>+31-71 5262410</phone>
    <email>p.hendriks@lumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <state>Zuid-Holland</state>
        <zip>2333ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Burgmans, MD, PhD</last_name>
      <phone>+31-71 5262410</phone>
      <email>m.c.burgmans@lumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Pim Hendriks, MSc.</last_name>
      <phone>+31-71 5298161</phone>
      <email>p.hendriks@lumc.nl</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 9, 2019</study_first_submitted>
  <study_first_submitted_qc>October 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 10, 2019</study_first_posted>
  <last_update_submitted>October 10, 2019</last_update_submitted>
  <last_update_submitted_qc>October 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Leiden University Medical Center</investigator_affiliation>
    <investigator_full_name>MCBurgmans</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No individual patiend data is shared with researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

